ERBB2 and ductal breast carcinoma in situ: For instance, in a randomized trial, neoadjuvant vaccination with HER2 peptide-pulsed DC1 cells caused 28.6% pathologic complete responses in HER2+ ductal breast carcinoma in situ (DCIS) patients [55].